Managing hypertension using home blood pressure monitoring among haemodialysis patients--a call to action.

risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–1305 32. Fort J. Chronic renal failure: a cardiovascular risk factor. Kidney Int Suppl 2005; S25–S29 33. Collins AJ, Foley RN, Herzog C et al. United States Renal Data System 2008 Annual Data Report Abstract. Am J Kidney Dis 2009; 53: S8–S374 34. Kasiske BL, Snyder JJ, Gilbertson DT et al. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905–913 35. Vajdic CM, McDonald SP, McCredie MR et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296: 2823–2831 36. Villeneuve PJ, Schaubel DE, Fenton SS et al. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant 2007; 7: 941–948 37. Branten AJW, du Buf-Vereijken PWG, Vervloet M et al. Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. American Journal of Kidney Diseases 2007; 50: 248–256 38. Ponticelli C, Passerini P, Salvadori M et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. American Journal of Kidney Diseases 2006; 47: 233–240 39. Eriguchi M, Oka H, Mizobuchi T et al. Long-term outcomes of idiopathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone. Nephrol Dial Transplant 2009; 24: 3082–3088 40. Warwick GL, Geddes CG, Boulton-Jones JM. Prednisolone and chlorambucil therapy for idiopathic membranous nephropathy with progressive renal failure. Q J Med 1994; 87: 223–229 41. Hofstra JM, Branten AJ, Wirtz JJ et al. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial. Nephrol Dial Transplant 2010; 25: 129–136